Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy
- PMID: 22672121
- DOI: 10.1111/j.1464-410X.2012.11216.x
Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy
Abstract
In many patients with prostate cancer, androgen deprivation therapy (ADT) is administered over prolonged periods of time. The benefits of long-term ADT in patients with advanced disease are well established and, more recently, studies have shown that long-term adjuvant ADT used in combination with radiotherapy improves survival in patients with earlier stages of disease. Nevertheless, clinicians should remain aware of the potential long-term side effects of ADT and the strategies that can be used to manage or prevent long-term complications. One such strategy is intermittent androgen deprivation (IAD), in which patients receive cycles of ADT, the duration of which is usually determined by PSA levels. Accumulating data indicate that this approach improves the tolerability of ADT (particularly sexual dysfunction) and patients' quality of life, without compromising clinical outcomes (progression and survival). Indeed, the latest European Association of Urology guidelines state that IAD should no longer be considered investigational. Nevertheless, some questions remain unanswered, including: who are the most suitable patients for IAD and what are the optimal PSA levels for stopping and restarting treatment? Osteoporosis (and the resultant increased risk of fractures) is a well-recognized complication of long-term ADT. Bone mineral density should be measured before and during long-term ADT and patients advised to make appropriate lifestyle changes to help preserve bone health. Pharmacological intervention is also an option. Denosumab (an NF-κB ligand inhibitor) significantly reduces ADT-induced bone loss and the risk of fractures in patients with non-metastatic disease. In those whose disease has metastasized, zoledronate and denosumab are licensed to prevent skeletal-related events and a large randomized study has shown that denosumab is more effective than zoledronate in this setting.
© 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL.
Similar articles
-
Androgen deprivation therapy: evidence-based management of side effects.BJU Int. 2013 Apr;111(4):543-8. doi: 10.1111/j.1464-410X.2012.11774.x. Epub 2013 Jan 25. BJU Int. 2013. PMID: 23351025 Review.
-
Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.Eur Urol. 2013 Nov;64(5):722-30. doi: 10.1016/j.eururo.2013.04.020. Epub 2013 Apr 19. Eur Urol. 2013. PMID: 23628492 Review.
-
Androgen deprivation therapy: past, present and future.BJU Int. 2012 Jun;109 Suppl 6:1-12. doi: 10.1111/j.1464-410X.2012.11215.x. BJU Int. 2012. PMID: 22672120 Review.
-
Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.BJU Int. 2012 Nov;110(9):1262-9. doi: 10.1111/j.1464-410X.2012.11120.x. Epub 2012 Apr 13. BJU Int. 2012. PMID: 22502816 Clinical Trial.
-
Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer.Urol Oncol. 2013 Jul;31(5):549-56. doi: 10.1016/j.urolonc.2011.03.008. Epub 2011 May 10. Urol Oncol. 2013. PMID: 21561791 Clinical Trial.
Cited by
-
Toward a health-promoting system for cancer survivors: Patient and provider multiple behavior change.Health Psychol. 2019 Sep;38(9):840-850. doi: 10.1037/hea0000760. Health Psychol. 2019. PMID: 31436465 Free PMC article. Review.
-
Implications of the Fracture Risk Assessment Algorithm for the assessment and improvement of bone health in patients with prostate cancer: A comprehensive review.Turk J Urol. 2019 Feb 20;45(4):245-253. doi: 10.5152/tud.2019.11736. Print 2019 Jul. Turk J Urol. 2019. PMID: 30817274 Free PMC article. Review.
-
The current status of hormone treatment for prostate cancer patients in Korean real-world practice: a multi-institutional observational study.Asian J Androl. 2019 Mar-Apr;21(2):115-120. doi: 10.4103/aja.aja_95_18. Asian J Androl. 2019. PMID: 30604695 Free PMC article.
-
Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.Eur J Nucl Med Mol Imaging. 2018 May;45(5):751-758. doi: 10.1007/s00259-017-3888-9. Epub 2017 Nov 30. Eur J Nucl Med Mol Imaging. 2018. PMID: 29192364
-
Fracture Risk in Prostate Cancer during Hormonal Therapy.Curr Urol. 2017 Jul;10(2):111-112. doi: 10.1159/000447162. Epub 2017 May 30. Curr Urol. 2017. PMID: 28785198 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous